Ceapro Inc., a biotechnology company, engages in the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using proprietary technology, natural, and renewable resources in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of the technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also develops and commercializes active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. The company was incorporated in 1997 and is headquartered in Edmonton, Canada. As of June 3, 2024, Ceapro Inc. operates as a subsidiary of Aeterna Zentaris Inc.
Frequently asked questions
What sector does Ceapro (CZO) operate in?
Ceapro belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ceapro (CZO) current stock price?
As of the latest data, Ceapro stock price is CA$6.20, with a previous close of CA$5.99. Ceapro gained CA$0.21 in the last trading session, representing a 3.51% increase.
What is Ceapro (CZO) current market capitalization?
Ceapro market cap is approximately 18.98 million.
What is Ceapro (CZO) Earnings Per Share (EPS)?
The trailing EPS is -CA$3.18.
Does Ceapro (CZO) pay dividends?
No. Ceapro does not pay a dividend.
What is Ceapro (CZO) beta (volatility) score?
Ceapro has a beta of 1.379, suggesting it is more volatile than the market.
